Earnings Feed
Start Free
Home/Filings/3/0001567619-20-009389
3//SEC Filing

Sarissa Capital Master Fund II LP 3

Accession 0001567619-20-009389

CIK 0001505512other
View on SEC.govCompany Profile

Filed

May 7, 8:00 PM ET

Accepted

May 8, 8:01 PM ET

Size

12.5 KB

Accession

0001567619-20-009389

Insider Transaction Report

Form 3
Period: 2020-04-01
Regulus Therapeutics Inc.RGLS
Sarissa Capital Master Fund II LP
10% Owner
Holdings

  • Common Stock

    76,356

  • Warrants to Purchase Common Stock

    Exercise: $1.08From: 2020-04-01Exp: 2024-05-07→ Common Stock (23,243 underlying)

  • Class A-2 Convertible Preferred Stock

    → Common Stock (5,311 underlying)

  • Warrants to Purchase Common Stock

    Exercise: $0.67From: 2020-04-01Exp: 2024-12-24→ Common Stock (53,113 underlying)
Footnotes (3)
  • [F1]See Exhibit 99.1
  • [F2]See Exhibit 99.1
  • [F3]See Exhibit 99.1

Documents

2 files

Issuer

Regulus Therapeutics Inc.

CIK 0001505512

→
Entity typeother
IncorporatedCayman Islands

Related Parties

1
  • filerCIK 0001811636

Filing Metadata

Form type
3
Filed
May 7, 8:00 PM ET
Accepted
May 8, 8:01 PM ET
Size
12.5 KB
View on SEC.gov